FilingsTodayJW Pharmaceutical
At a glance
JW Pharmaceutical filed 42 disclosures in the last 12 months, including 3 earnings, 2 insider and 2 5% holder. The most recent key filing was on Sep 17.
Revenue for 2025 was ₩775B, up 7.8% on 2024. Operating margin was 12.2% against 11.5% a year earlier. Debt was 64% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩422B and operating profit of ₩66.9B.
The 2025 annual report lists 1,106 employees with an average tenure of 8.8 years and average pay of ₩64.2M, #796 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩285M each on average. It paid ₩650 per common share in cash dividends, against ₩450 a year earlier (+44.4%). JW홀딩스(주) and related parties held 41.01% at year end.
From the 2025 annual report
Staff: 1,106 (785 men, 321 women), of whom 39 on fixed-term contracts. Total pay for the year: ₩70.3B. Directors and auditors: 6, paid ₩1.7B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩650 | ₩450 | ₩400 |
| Payout ratio | 25.5% | 17% | 25.1% |
| Yield (as filed) | 2.10% | 1.90% | 1.10% |
| Total cash dividends | ₩15.7B | ₩11.1B | ₩9.7B |
Largest shareholder
JW홀딩스(주) holds 40.25%; with 8 related parties the group holds 41.01% of common shares at year end (from 41.04% at the start of the year).
Individuals paid ₩500M or more
| 이경하 등기이사 | ₩1.1B |
Auditor: 한영회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.